DE60040352D1 - Rekombinante virale vektoren mit dem gen für den menschlichen urokinase-plasminaktivator und deren verwendung bei der behandlung von leberfibrose - Google Patents

Rekombinante virale vektoren mit dem gen für den menschlichen urokinase-plasminaktivator und deren verwendung bei der behandlung von leberfibrose

Info

Publication number
DE60040352D1
DE60040352D1 DE60040352T DE60040352T DE60040352D1 DE 60040352 D1 DE60040352 D1 DE 60040352D1 DE 60040352 T DE60040352 T DE 60040352T DE 60040352 T DE60040352 T DE 60040352T DE 60040352 D1 DE60040352 D1 DE 60040352D1
Authority
DE
Germany
Prior art keywords
gene
treatment
viral vectors
liver fibrosis
recombinant viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60040352T
Other languages
English (en)
Inventor
Borunda Juan Armendariz
Cordova Estuardo Aguilar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TGT Laboratories SA de CV
Original Assignee
TGT Laboratories SA de CV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TGT Laboratories SA de CV filed Critical TGT Laboratories SA de CV
Application granted granted Critical
Publication of DE60040352D1 publication Critical patent/DE60040352D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1833Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/6456Plasminogen activators
    • C12N9/6462Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21073Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
DE60040352T 2000-11-28 2000-11-30 Rekombinante virale vektoren mit dem gen für den menschlichen urokinase-plasminaktivator und deren verwendung bei der behandlung von leberfibrose Expired - Lifetime DE60040352D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MXPA00011713A MXPA00011713A (es) 2000-11-28 2000-11-28 Vectores recombinantes virales y no virales conteniendo el gen humano del activador de plasminogeno derivado de urocinasa y su utilidad en el tratamiento de diversos tipos de fibrosis hepatica, renal, pulmonar, pancreatica, cardiaca y cicatrices hipe
PCT/MX2000/000050 WO2002044393A1 (es) 2000-11-28 2000-11-30 Vectores recombinantes virales y no-virales conteniendo el gen humano del activador de plasminogeno derivado de urocinasa y su utilidad en el tratamiento de diversos tipos de fibrosis hepatica, renal, pulmonar, pancreatica, cardiaca y cicatrices hipertroficas

Publications (1)

Publication Number Publication Date
DE60040352D1 true DE60040352D1 (de) 2008-11-06

Family

ID=32294070

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60040352T Expired - Lifetime DE60040352D1 (de) 2000-11-28 2000-11-30 Rekombinante virale vektoren mit dem gen für den menschlichen urokinase-plasminaktivator und deren verwendung bei der behandlung von leberfibrose
DE00980071T Pending DE00980071T1 (de) 2000-11-28 2000-11-30 Rekombinate virale und nichvirale Vektoren, die das Gen für den humanen Urokinase-Plasminogen-Aktivator enthalten, und ihre Verwenung bei der Behandlung verschiedener Arten von Leber-, Nieren-, Lungen-Pankreas- und Herzfibrose sowie hypertrophen Narben

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE00980071T Pending DE00980071T1 (de) 2000-11-28 2000-11-30 Rekombinate virale und nichvirale Vektoren, die das Gen für den humanen Urokinase-Plasminogen-Aktivator enthalten, und ihre Verwenung bei der Behandlung verschiedener Arten von Leber-, Nieren-, Lungen-Pankreas- und Herzfibrose sowie hypertrophen Narben

Country Status (16)

Country Link
US (1) US7807457B2 (de)
EP (1) EP1411128B1 (de)
JP (1) JP4733337B2 (de)
AR (1) AR031436A1 (de)
AT (1) ATE409234T1 (de)
AU (1) AU2001217374A1 (de)
CA (1) CA2430367C (de)
CY (1) CY1108667T1 (de)
DE (2) DE60040352D1 (de)
DK (1) DK1411128T3 (de)
ES (1) ES2226597T3 (de)
HK (1) HK1062454A1 (de)
MX (1) MXPA00011713A (de)
PT (1) PT1411128E (de)
TR (1) TR200403256T3 (de)
WO (1) WO2002044393A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1391214A4 (de) * 2001-05-09 2006-05-17 Anges Mg Inc Gentransfer des angiogenen faktors bei hauterkrankungen
WO2007094071A1 (ja) * 2006-02-17 2007-08-23 Tokyo University Of Agriculture And Technology Tlo Co., Ltd. 肝機能改善剤
EP2747551B1 (de) 2011-08-26 2020-02-12 Yecuris Corporation Fumarylacetoacetat-hydrolase (fah)-defiziente und immundefiziente ratten sowie ihre verwendung
CA2995132C (en) * 2016-01-28 2020-04-21 Tianjin International Joint Academy Of Biotechnology & Medicine Method for treating pulmonary fibrosis comprising application of dimethylamino micheliolide
EP3468605A4 (de) * 2016-06-08 2020-01-08 President and Fellows of Harvard College Manipulierter viraler vektor zur reduzierung von induktion von entzündungs- und immunreaktionen
CN108210897A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 预防和治疗肺纤维化的药物及其用途
US20190314466A1 (en) 2016-12-15 2019-10-17 Talengen International Limited Method for preventing and treating skin fibrosis
KR20210110848A (ko) 2018-12-28 2021-09-09 카탈리스트 바이오사이언시즈, 인코포레이티드 변형된 유로키나제 유형 플라스미노겐 활성제 폴리펩타이드 및 사용 방법
US11613744B2 (en) 2018-12-28 2023-03-28 Vertex Pharmaceuticals Incorporated Modified urokinase-type plasminogen activator polypeptides and methods of use

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166320A (en) * 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US5240846A (en) * 1989-08-22 1993-08-31 The Regents Of The University Of Michigan Gene therapy vector for cystic fibrosis
US5585362A (en) * 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5670488A (en) * 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5521291A (en) * 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
IL105914A0 (en) * 1992-06-04 1993-10-20 Univ California Methods and compositions for in vivo gene therapy
GB9223084D0 (en) * 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
US5543328A (en) * 1993-08-13 1996-08-06 Genetic Therapy, Inc. Adenoviruses having modified fiber proteins
DE4339922C1 (de) * 1993-09-03 1994-10-06 Max Planck Gesellschaft Vektor für Leber-Gentherapie
US6686198B1 (en) * 1993-10-14 2004-02-03 President And Fellows Of Harvard College Method of inducing and maintaining neuronal cells
US5559099A (en) * 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5846782A (en) * 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5856152A (en) * 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
US5910487A (en) * 1994-12-09 1999-06-08 Genzyme Corporation Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules
US5980886A (en) * 1994-12-14 1999-11-09 University Of Washington Recombinant vectors for reconstitution of liver
US6107027A (en) * 1994-12-14 2000-08-22 University Of Washington Ribozymes for treating hepatitis C
US5770442A (en) * 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
US5872154A (en) * 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus
US6265212B1 (en) * 1995-06-15 2001-07-24 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
WO1997017090A1 (en) 1995-11-07 1997-05-15 Baylor College Of Medicine Adenovirus-mediated production of bioactive proteins by mammalian cells and animals
US6020191A (en) * 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
BR9808934A (pt) * 1997-04-18 2000-08-01 Biogen Inc Proteìnas de fusão de região constante de receptor/imunoglobulina tgf-beta do tipo ii
US5922576A (en) * 1998-02-27 1999-07-13 The John Hopkins University Simplified system for generating recombinant adenoviruses
WO1999055382A1 (en) * 1998-04-29 1999-11-04 The Uab Research Foundation Adenoviral vector encoding anti-apoptotic bcl-2 gene and uses thereof

Also Published As

Publication number Publication date
PT1411128E (pt) 2008-12-30
EP1411128A1 (de) 2004-04-21
DE00980071T1 (de) 2005-03-31
MXPA00011713A (es) 2002-05-31
DK1411128T3 (da) 2009-02-02
JP2004527224A (ja) 2004-09-09
CA2430367C (en) 2012-10-30
AU2001217374A1 (en) 2002-06-11
ATE409234T1 (de) 2008-10-15
EP1411128B1 (de) 2008-09-24
ES2226597T3 (es) 2009-03-16
AR031436A1 (es) 2003-09-24
ES2226597T1 (es) 2005-04-01
CY1108667T1 (el) 2014-04-09
CA2430367A1 (en) 2002-06-06
US20040097455A1 (en) 2004-05-20
US7807457B2 (en) 2010-10-05
WO2002044393A1 (es) 2002-06-06
HK1062454A1 (en) 2004-11-05
JP4733337B2 (ja) 2011-07-27
TR200403256T3 (tr) 2005-02-21

Similar Documents

Publication Publication Date Title
ATE374204T1 (de) Thienopyrimidinedione und deren verwendung in der behandlung von autoimmunerkrankungen
DE69826811D1 (de) Zusammensetzungen für die Verwendung bei der Behandlung und Prävention von Hyperurikämie
ATE415392T1 (de) Pyrimidinonderivate und deren verwendung bei der behandlung von atherosklerose
DE60331049D1 (de) Konjugate von zytotoxischen mitteln und biologisch aktiven peptiden
DE60223715D1 (de) Glyt1 transporter inhibitoren und deren anwendung in der behandlung von neurologischen und neuropsychiatischen krankheiten
BR0107691A (pt) Sapogeninas substituìdas e seu uso
NO20013888D0 (no) Kunstige peptider som har overflateaktivitet og anvendelse derav i fremstillingen av kunstig surfaktant
DE60137929D1 (de) Verwendung von lanthan bei der behandlung von knochenerkrankungen
ATE332143T1 (de) Verwendung von lactobacillus casei in immunverstärkenden zusammensetzungen
DE69912609D1 (de) Behandlung von in der luft enthaltenen mikroorganismen
DE60040352D1 (de) Rekombinante virale vektoren mit dem gen für den menschlichen urokinase-plasminaktivator und deren verwendung bei der behandlung von leberfibrose
DE50002478D1 (de) Neue kombination von loteprednol und antihistaminika
DE69829763D1 (de) Verwendung von tetrahydolipstatin in der behandlung von diabetes typ ii
DE60327254D1 (de) Den getreideertrag erhöhendes gen und dessen nutzung
DE69840932D1 (de) Zusammensetzungen und verfahren zur verstärkung der verabreichung von therapeutischen mitteln in zellen
ATE289749T1 (de) Verwendung von polysiloxanen mit quartären aminogruppen als formulierungshilfsmittel und mittel enthaltend dieselben
DE60017133D1 (de) Naphthochinonderivate und ihre verwendung zur behandlung und kontrolle von tuberkulose
DE69821685D1 (de) Ethanolische Lösungen von N-Pentadecanoylisoleucin und Verwendung derselben in der Kosmetik
EE04055B1 (et) Ühendid ja kompositsioonid seriinproteaasse, eriti trüptaasse aktiivsusega seotud haiguste raviks, ja nende kasutamine
PL366855A1 (en) Combination preparations of aryl substituted propanolamine derivatives with other active ingredients and the use thereof
ATE298339T1 (de) ß3,7-DIAZABICYCLO(3.3.0)OCTANE UND DEREN VERWENDUNG BEI DER BEHANDLUNG VON HERZRHYTHMUSSTÖRUNGENß
ATE323685T1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
DE69919414D1 (de) Inverser latex und verwendung in der kosmetik
DE69517345D1 (de) Abziehbarer Verbundstoff und seiner Verwendung bei der Herstellung von Ausgleichsscheiben
DE60017924D1 (de) Rekombinante, adenovirale vektoren und ihre verwendung zur behandlung von leberzirrhose

Legal Events

Date Code Title Description
8364 No opposition during term of opposition